This trial is looking to examine the effectiveness of carboplatin (Paraplatin), paclitaxel (Taxol), and ramucirumab (Cyramza) in the treatment of advanced non-squamous non-small cell lung cancer (NSCLC) that is progressive after maintenance therapy. The main outcome that is to be measured is the response of the patients to the treatment. This trial is being conducted in Pennsylvania, the United States.
NSCLC is a form of lung cancer. It is responsible for 85% of all lung cancer diagnoses. The standard treatment for NSCLC is the surgical removal of tumors, chemotherapy, and radiotherapy, or a combination of them. Despite existing treatment options, NSCLC can be difficult to treat.
Carboplatin is a platinum-based chemotherapy. Ramucirumab is an immune protein that can be used to shrink solid tumors. Paclitaxel is a taxane. Taxanes are a type of chemotherapy. This trial is examining the effectiveness of the combination of carboplatin, paclitaxel, and ramucirumab in patients with progressive NSCLC. The main outcome that is to be measured is the response rate of patients tumors to the therapy.
Who are they looking for?
This trial is looking to recruit 59 participants with advanced NSCLC. Participants must have prior exposure to 4-6 cycles of pemetrexed (Alimta)/carboplatin/pembrolizumab (Keytruda) after at least 18 weeks of maintenance pemetrexed, pembrolizumab, or the combination of the two.
Patients will be excluded from the trial if they have a genetic mutation (abnormal gene) that can be treated with targeted therapy. Other cancers, cancer spread to the brain, a history of bleeding disorders or sensory nerve damage are other exclusion criteria.
How will it work
There will be one group in this trial. All patients will be given a combination of carboplatin, paclitaxel, and ramucirumab every three weeks. All drugs will be administered intravenously (as an injection into the vein). Follow-up in this trial will be up to 3 years.
The main outcomes measured will be response to treatment, survival and side effects.